Russia Faces Growing Concerns Over Pharmaceutical Quality and Access
Russia is experiencing a deepening crisis in its pharmaceutical sector, marked by dwindling access to imported medications, questions about the quality of domestically produced drugs, and controversial cost-cutting measures.
Recent reports indicate a growing disparity between those who can afford and access quality healthcare and those who cannot, with some patients resorting to desperate measures to obtain necessary medications. Concerns have been raised about the efficacy of Russian-made drugs, with some patients expressing a preference for imported alternatives even at significantly higher costs. The situation highlights a long-standing issue of trust in the quality of Russian pharmaceuticals, dating back to Soviet times. A State Duma Budget Committee member, Airat Farrakhov, recently proposed selling pills individually to reduce expenses, a suggestion met with skepticism and concern.
The Health Ministry maintains that domestic equivalents are available, but critics argue that chronic illnesses often require individualized treatment plans and that substituting drugs can have detrimental effects. Dmitry Kudlai, vice president of Generium, voiced frustration at the Eastern Economic Forum regarding the underperformance of his company’s Gaucher’s disease treatment, Glurazym, compared to the Irish-made Vpriv, despite serving the same purpose. A new rule prioritizing Russian manufacturers in government tenders, known as the “second is superfluous” rule, is set to expand in 2026, potentially further limiting access to imported drugs. This policy shift could exacerbate existing shortages and drive up costs for patients. For more information on the Russian healthcare system, see The World Bank’s overview of Russia’s health system.
Further compounding the issue, reports have surfaced of bureaucratic obstacles hindering access to even basic medical supplies. In Krasnodar Krai, a tender for syringes was reportedly challenged by the Federal Antimonopoly Service (FAS) for requiring plastic needle caps – a standard safety feature not currently produced by Russian manufacturers. This incident, along with plans to restrict imports of stents and catheters, raises serious questions about patient safety and the prioritization of national interests over public health. The Moscow Times recently reported on broader concerns regarding independence within Russian institutions.
Officials have stated that efforts are underway to strengthen the domestic pharmaceutical industry, but concerns remain about the ability of Russian manufacturers to meet the demand for high-quality, affordable medications. The Health Ministry has promised to “do everything necessary” to ensure resources remain within the country.
